09/23/2015 1 Mergent, Inc. Johnson & Johnson General Company Information Principal Office One Johnson & Johnson Plaza New Brunswick, NJ 08933 USA Phone 732 524-0400 Fax 732 214-0332 Auditor PricewaterhouseCoopers LLP Number of Employees 126,500 (Approximate Full-Time as of 12/31/2014) Country of Incorporation United States Exchange And Ticker NYS : JNJ Primary SIC 2834 : Pharmaceutical preparations Company Website www.jnj.com Primary NAICS 325412 : Pharmaceutical Preparation Manufacturing Closing Stock Price 93.24 (as of 09/22/2015) Incorporated November 1887 , NJ, United States Mergent Dividend Achiever Yes, # of Years: 46 Number of Shareholders 162,062 (record) (as of 02/17/2015) Business Summary Johnson & Johnson is a holding company. Through its subsidiaries, Co. is organized into three segments. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women's health and wound care markets. The Pharmaceutical segment is focused on five therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, and cardiovascular and metabolic diseases. The Medical Devices segment includes a range of products used in the orthopaedic, surgical care, specialty surgery, cardiovascular care, diagnostics, diabetes care, and vision care markets, which are distributed to wholesalers, hospitals and retailers. Johnson & Johnson 09/23/2015 2 Mergent, Inc. Pricing Information Closing Price As of 09/22/2015 : 93.24 Dividend Yield 3.1103 Earning Per Share(TTM) 5.78 Dividend Per Share(TTM) 2.9 Market Cap(mil) 258,191 52 Week Range 90.73 - 109.07 PE Ratio 16.3866 % Price Change (100 Days) -4.36 09/23/2015 1 Mergent, Inc. Johnson & Johnson General Company Information Principal Office One Johnson & Johnson Plaza New Brunswick, NJ 08933 USA Phone 732 524-0400 Fax 732 214-0332 Auditor PricewaterhouseCoopers LLP Number of Employees 126,500 (Approximate Full-Time as of 12/31/2014) Country of Incorporation United States Exchange And Ticker NYS : JNJ Primary SIC 2834 : Pharmaceutical preparations Company Website www.jnj.com Primary NAICS 325412 : Pharmaceutical Preparation Manufacturing Closing Stock Price 93.24 (as of 09/22/2015) Incorporated November 1887 , NJ, United States Mergent Dividend Achiever Yes, # of Years: 46 Number of Shareholders 162,062 (record) (as of 02/17/2015) Business Summary Johnson & Johnson is a holding company. Through its subsidiaries, Co. is organized into three segments. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women's health and wound care markets. The Pharmaceutical segment is focused on five therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, and cardiovascular and metabolic diseases. The Medical Devices segment includes a range of products used in the ortho ...

1. 09/23/2015 1 Mergent, Inc.
Johnson & Johnson
General Company Information
Principal Office
One Johnson & Johnson Plaza
New Brunswick, NJ 08933 USA
Phone 732 524-0400
Fax 732 214-0332
Auditor
PricewaterhouseCoopers LLP
Number of Employees
126,500 (Approximate Full-Time as of 12/31/2014)
Country of Incorporation
United States
Exchange And Ticker
NYS : JNJ
Primary SIC
2834 : Pharmaceutical preparations
Company Website
www.jnj.com

2. Primary NAICS
325412 : Pharmaceutical Preparation Manufacturing
Closing Stock Price 93.24 (as of 09/22/2015)
Incorporated
November 1887 , NJ, United States
Mergent Dividend Achiever Yes, # of Years: 46
Number of Shareholders
162,062 (record) (as of 02/17/2015)
Business Summary
Johnson & Johnson is a holding company. Through its
subsidiaries, Co. is organized into three segments.
The Consumer segment includes a range of products used in the
baby care, oral care, skin care,
over-the-counter pharmaceutical, women's health and wound
care markets. The Pharmaceutical segment
is focused on five therapeutic areas, including immunology,
infectious diseases, neuroscience, oncology,
and cardiovascular and metabolic diseases. The Medical
Devices segment includes a range of products
used in the orthopaedic, surgical care, specialty surgery,
cardiovascular care, diagnostics, diabetes care,
and vision care markets, which are distributed to wholesalers,
hospitals and retailers.
Johnson & Johnson
09/23/2015 2 Mergent, Inc.

3. Pricing Information
Closing Price
As of 09/22/2015 : 93.24
Dividend Yield
3.1103
Earning Per Share(TTM)
5.78
Dividend Per Share(TTM)
2.9
Market Cap(mil)
258,191
52 Week Range
90.73 - 109.07
PE Ratio
16.3866
% Price Change (100 Days)
-4.36
09/23/2015 1 Mergent, Inc.
Johnson & Johnson
General Company Information

4. Principal Office
One Johnson & Johnson Plaza
New Brunswick, NJ 08933 USA
Phone 732 524-0400
Fax 732 214-0332
Auditor
PricewaterhouseCoopers LLP
Number of Employees
126,500 (Approximate Full-Time as of 12/31/2014)
Country of Incorporation
United States
Exchange And Ticker
NYS : JNJ
Primary SIC
2834 : Pharmaceutical preparations
Company Website
www.jnj.com
Primary NAICS
325412 : Pharmaceutical Preparation Manufacturing
Closing Stock Price 93.24 (as of 09/22/2015)
Incorporated
November 1887 , NJ, United States
Mergent Dividend Achiever Yes, # of Years: 46

5. Number of Shareholders
162,062 (record) (as of 02/17/2015)
Business Summary
Johnson & Johnson is a holding company. Through its
subsidiaries, Co. is organized into three segments.
The Consumer segment includes a range of products used in the
baby care, oral care, skin care,
over-the-counter pharmaceutical, women's health and wound
care markets. The Pharmaceutical segment
is focused on five therapeutic areas, including immunology,
infectious diseases, neuroscience, oncology,
and cardiovascular and metabolic diseases. The Medical
Devices segment includes a range of products
used in the orthopaedic, surgical care, specialty surgery,
cardiovascular care, diagnostics, diabetes care,
and vision care markets, which are distributed to wholesalers,
hospitals and retailers.
Johnson & Johnson
09/23/2015 2 Mergent, Inc.
Pricing Information
Closing Price
As of 09/22/2015 : 93.24
Dividend Yield
3.1103
Earning Per Share(TTM)

6. 5.78
Dividend Per Share(TTM)
2.9
Market Cap(mil)
258,191
52 Week Range
90.73 - 109.07
PE Ratio
16.3866
% Price Change (100 Days)
-4.36
09/23/2015 1 Mergent, Inc.
Johnson & Johnson
General Company Information
Principal Office
One Johnson & Johnson Plaza
New Brunswick, NJ 08933 USA
Phone 732 524-0400
Fax 732 214-0332
Auditor

7. PricewaterhouseCoopers LLP
Number of Employees
126,500 (Approximate Full-Time as of 12/31/2014)
Country of Incorporation
United States
Exchange And Ticker
NYS : JNJ
Primary SIC
2834 : Pharmaceutical preparations
Company Website
www.jnj.com
Primary NAICS
325412 : Pharmaceutical Preparation Manufacturing
Closing Stock Price 93.24 (as of 09/22/2015)
Incorporated
November 1887 , NJ, United States
Mergent Dividend Achiever Yes, # of Years: 46
Number of Shareholders
162,062 (record) (as of 02/17/2015)
Business Summary
Johnson & Johnson is a holding company. Through its
subsidiaries, Co. is organized into three segments.
The Consumer segment includes a range of products used in the
baby care, oral care, skin care,

8. over-the-counter pharmaceutical, women's health and wound
care markets. The Pharmaceutical segment
is focused on five therapeutic areas, including immunology,
infectious diseases, neuroscience, oncology,
and cardiovascular and metabolic diseases. The Medical
Devices segment includes a range of products
used in the orthopaedic, surgical care, specialty surgery,
cardiovascular care, diagnostics, diabetes care,
and vision care markets, which are distributed to wholesalers,
hospitals and retailers.
Johnson & Johnson
09/23/2015 2 Mergent, Inc.
Executives
Officers
Alex Gorsky
Title : Chairman
Tenure : 27 Age : 55
Total Compensation : $61,989,306 %Change : 2.67
Education : -
Dominic J. Caruso
Title : Vice President
Tenure : 16 Age : 57
Total Compensation : $10,349,033 %Change : 0.26
Education : -
Peter M. Fasolo
Title : Vice President
Tenure : 5 Age : 52

9. Total Compensation : $3,621,281 %Change : -
Education : -
Michael H. Ullmann
Title : Vice President
Tenure : 26 Age : 57
Total Compensation : $5,960,691 %Change : 0.37
Education : -
Paulus Stoffels
Title : Chief Scientific Officer
Tenure : 13 Age : 53
Total Compensation : $18,339,317 %Change : 1.34
Education : -
Stephen J. Cosgrove
Title : Chief Accounting Officer
Tenure : - Age : -
Total Compensation : $- %Change : -
Education : -
Sandra E. Peterson
Title : Group Worldwide Chair
Tenure : 3 Age : 56
Total Compensation : $7,086,606 %Change : 0.26
Education : -
Douglas K. Chia
Title : Secretary
Tenure : 9 Age : -
Total Compensation : $- %Change : -
Education : -
Johnson & Johnson

10. 09/23/2015 3 Mergent, Inc.
Ronald A. Kapusta
Title : Division Officer
Tenure : 23 Age : 56
Total Compensation : $- %Change : -
Education : -
Lacey P. Elberg
Title : Assistant Secretary
Tenure : - Age : -
Total Compensation : $- %Change : -
Education : -
William C. Weldon - Inactive (Stepped Down)
Title :
Tenure : 44 Age : 66
Total Compensation : $29,838,259 %Change : 0.11
Education : -
Christine A. Poon - Inactive (Retired)
Title : Vice-Chairman
Tenure : 15 Age : 62
Total Compensation : $10,402,493 %Change : -0.01
Education : -
Robert J. Darretta - Inactive (Retired)
Title : Vice-Chairman
Tenure : 47 Age : 68
Total Compensation : $11,263,525 %Change : 1.84
Education : -
Russell C. Deyo - Inactive (Retired)
Title :
Tenure : 30 Age : 65

11. Total Compensation : $8,975,035 %Change : 0.01
Education : -
Roger S. Fine - Inactive (Retired)
Title : Vice President
Tenure : 41 Age : 67
Total Compensation : $- %Change : -
Education : -
Nicholas J. Valeriani - Inactive (Not Reported)
Title : Vice President
Tenure : 37 Age : 58
Total Compensation : $- %Change : -
Education : -
Kaye I. Foster-Cheek - Inactive (Not Reported)
Title : Vice President
Tenure : 12 Age : 55
Johnson & Johnson
09/23/2015 4 Mergent, Inc.
Total Compensation : $- %Change : -
Education : -
JoAnn Heffernan Heisen - Inactive (Not Reported)
Title : Vice President
Tenure : 26 Age : 65
Total Compensation : $- %Change : -
Education : -
Steven M. Rosenberg - Inactive (Not Reported)
Title : Secretary

12. Tenure : - Age : -
Total Compensation : $- %Change : -
Education : -
Sherilyn S. McCoy - Inactive (Resigned)
Title :
Tenure : 33 Age : 56
Total Compensation : $8,733,678 %Change : 0.16
Education : -
Colleen A. Goggins - Inactive (Retired)
Title : Division Officer
Tenure : 34 Age : 60
Total Compensation : $7,738,614 %Change : -0.07
Education : -
Donald M. Casey - Inactive (Not Reported)
Title : Division Officer
Tenure : 30 Age : -
Total Compensation : $- %Change : -
Education : -
Christian A. Koffmann - Inactive (Not Reported)
Title : Division Officer
Tenure : 26 Age : 66
Total Compensation : $- %Change : -
Education : -
Joseph C. Scodari - Inactive (Retired)
Title : Division Officer
Tenure : 16 Age : 62
Total Compensation : $- %Change : -
Education : -
Per A. Peterson - Inactive (Retired)
Title : Division Officer

13. Tenure : 21 Age : 70
Total Compensation : $8,700,118 %Change : 1.84
Education : -
Johnson & Johnson
09/23/2015 5 Mergent, Inc.
Michael J. Dormer - Inactive (Retired)
Title : Division Officer
Tenure : 17 Age : 63
Total Compensation : $3,005,443 %Change : 0.68
Education : -
Directors
Alex Gorsky
Title : Chairman
Tenure : 27 Age : 55
Total Compensation : $61,989,306 %Change : 2.67
Education : -
Mary Sue Coleman
Title : Director
Tenure : 12 Age : 71
Total Compensation : $284,924 %Change : 0.03
Education : -
D. Scott Davis
Title : Director
Tenure : 1 Age : 63
Total Compensation : $264,924 %Change : -
Education : -

14. Ian E. L. Davis
Title : Director
Tenure : 5 Age : 64
Total Compensation : $58,366 %Change : -0.77
Education : -
Susan L. Lindquist
Title : Director
Tenure : 11 Age : 65
Total Compensation : $286,324 %Change : 0.04
Education : -
Mark B. McClellan
Title : Director
Tenure : 2 Age : 51
Total Compensation : $264,924 %Change : 8.63
Education : -
Anne M. Mulcahy
Title : Director
Tenure : 6 Age : 62
Total Compensation : $324,924 %Change : 0.14
Education : -
Johnson & Johnson
09/23/2015 6 Mergent, Inc.
William D. Perez
Title : Director
Tenure : 8 Age : 68
Total Compensation : $284,924 %Change : -0.03
Education : -

15. Charles Prince
Title : Director
Tenure : 9 Age : 65
Total Compensation : $284,924 %Change : -0.04
Education : -
A. Eugene Washington
Title : Director
Tenure : 3 Age : 64
Total Compensation : $266,924 %Change : 0.02
Education : -
Ronald A. Williams
Title : Director
Tenure : 4 Age : 66
Total Compensation : $284,924 %Change : 0.12
Education : -
Mary C. Beckerle
Title : Director
Tenure : - Age : 60
Total Compensation : $- %Change : -
Education : -
William C. Weldon - Inactive (Will Not Stand For Re-election)
Title :
Tenure : 44 Age : 66
Total Compensation : $29,838,259 %Change : 0.11
Education : -
Christine A. Poon - Inactive (Retired)
Title : Vice-Chairman
Tenure : 15 Age : 62
Total Compensation : $10,402,493 %Change : -0.01
Education : -

16. Robert J. Darretta - Inactive (Retired)
Title : Vice-Chairman
Tenure : 47 Age : 68
Total Compensation : $11,263,525 %Change : 1.84
Education : -
James G. Cullen - Inactive (Not Standing For Re-election)
Title :
Tenure : 20 Age : 72
Johnson & Johnson
09/23/2015 7 Mergent, Inc.
Total Compensation : $289,924 %Change : -0.03
Education : -
David Satcher - Inactive (Not Standing For Re-election)
Title :
Tenure : 13 Age : 74
Total Compensation : $203,903 %Change : -0.28
Education : -
Leo F. Mullin - Inactive (Not Standing For Re-election)
Title :
Tenure : 16 Age : 72
Total Compensation : $284,924 %Change : -0.04
Education : -
Michael M. E. Johns - Inactive (Not Standing For Re-election)
Title :
Tenure : 10 Age : 73
Total Compensation : $211,591 %Change : -0.20
Education : -

17. Henry B. Schacht - Inactive (Retired)
Title :
Tenure : 18 Age : 80
Total Compensation : $- %Change : -
Education : -
Arnold G. Langbo - Inactive (Resigned)
Title :
Tenure : 24 Age : 77
Total Compensation : $142,442 %Change : -0.39
Education : -
Steven S. Reinemund - Inactive (Resigned)
Title :
Tenure : 12 Age : 67
Total Compensation : $259,875 %Change : 0.23
Education : -
Ann Dibble Jordan - Inactive (Retired)
Title :
Tenure : 34 Age : 80
Total Compensation : $144,131 %Change : -0.31
Education : -
M. Judah Folkman - Inactive (Not Reported)
Title :
Tenure : 17 Age : 81
Total Compensation : $- %Change : -
Education : -
Johnson & Johnson
09/23/2015 8 Mergent, Inc.

18. Gerard N. Burrow - Inactive (Not Reported)
Title :
Tenure : 22 Age : 81
Total Compensation : $- %Change : -
Education : -
Commitees
Audit Committee
Anne Mulcahy
D. Davis
Ian Davis
Mary Coleman
Benefits & Compensation Committee
Charles Prince
Ronald Williams
William Perez
Corporate Governance & Nominating Committee
Anne Mulcahy
Charles Prince
William Perez
Finance Committee
Alex Gorsky
Anne Mulcahy
Public Policy Committee
Science & Technology Committee
A. Washington
Ian Davis
Mark McClellan
Mary Coleman

19. Susan Lindquist
Executive Compensation
Officers
Alex Gorsky
Compensation History
Year Values in USD 2014 2013 2012
Salary 1,500,000 1,453,846 1,087,188
Stock Awards 9,467,380 5,988,975 2,790,229
Option Awards 41,168,139 2,669,999 1,482,631
Non-Equity Incentive Plan 5,018,779 4,867,361 3,407,287
Johnson & Johnson
09/23/2015 9 Mergent, Inc.
Year Values in USD 2014 2013 2012
Compensation
Change in Pension Value & 4,606,142 1,739,000 2,050,000
Non-Qualified Deferred Comp. Earni
All Other Compensation 228,866 191,779 159,774
Total Compensation 61,989,306 16,910,960 10,977,109
Dominic J. Caruso
Compensation History
Year Values in USD 2014 2013 2012
Salary 878,115 842,308 796,385
Stock Awards 3,271,853 2,663,229 2,089,563
Option Awards 1,332,376 1,139,999 1,110,303

20. Non-Equity Incentive Plan 3,234,152 3,222,866 3,014,577
Compensation
Change in Pension Value & 1,511,238 252,000 915,000
Non-Qualified Deferred Comp. Earni
All Other Compensation 121,299 112,911 84,009
Total Compensation 10,349,033 8,233,313 8,009,837
Peter M. Fasolo
Compensation History
Year Values in USD 2012
Salary 534,769
Stock Awards 1,387,098
Option Awards 737,042
Non-Equity Incentive Plan 715,209
Compensation
Change in Pension Value & 214,000
Non-Qualified Deferred Comp. Earni
All Other Compensation 33,163
Total Compensation 3,621,281
Michael H. Ullmann
Compensation History
Year Values in USD 2014 2013
Salary 591,346 542,308
Stock Awards 1,615,191 1,390,982
Option Awards 721,877 656,248
Non-Equity Incentive Plan 1,502,105 1,348,953
Compensation
Change in Pension Value & 1,494,001 394,000

21. Johnson & Johnson
09/23/2015 10 Mergent, Inc.
Year Values in USD 2014 2013
Non-Qualified Deferred Comp. Earni
All Other Compensation 36,171 30,845
Total Compensation 5,960,691 4,363,336
Paulus Stoffels
Compensation History
Year Values in USD 2014 2013 2012
Salary 1,075,423 952,923 825,385
Stock Awards 10,690,520 2,580,466 1,926,252
Option Awards 1,307,669 1,109,999 1,023,570
Non-Equity Incentive Plan 2,573,450 2,416,809 2,305,251
Compensation
Change in Pension Value & 2,267,167 357,000 1,095,000
Non-Qualified Deferred Comp. Earni
All Other Compensation 425,088 404,802 161,466
Total Compensation 18,339,317 7,821,999 7,336,924
Stephen J. Cosgrove
Sandra E. Peterson
Compensation History
Year Values in USD 2014 2013 2012
Salary 841,346 800,000 46,154
Bonus N/A 1,900,000 300,000
Stock Awards 2,833,545 635,867 4,300,017
Option Awards 1,368,001 299,998 N/A
Non-Equity Incentive Plan 1,400,000 1,200,000 N/A

22. Compensation
Change in Pension Value & 451,000 274,000 N/A
Non-Qualified Deferred Comp. Earni
All Other Compensation 192,714 527,396 52,679
Total Compensation 7,086,606 5,637,261 4,698,850
Douglas K. Chia
Ronald A. Kapusta
Lacey P. Elberg
Johnson & Johnson
09/23/2015 11 Mergent, Inc.
William C. Weldon
Compensation History
Year Values in USD 2012 2011 2010
Salary 1,320,578 1,907,215 1,851,154
Bonus N/A N/A N/A
Other Annual Compensation/Fees N/A N/A N/A
Stock Awards 7,565,328 2,608,694 2,773,851
Option Awards 4,019,999 4,189,483 4,713,177
Restricted Stock Units N/A N/A N/A
Underlying Options/SARs (# of N/A N/A N/A
Securities)
Non-Equity Incentive Plan 13,447,666 14,336,394 12,043,200
Compensation
Change in Pension Value & 3,250,000 3,435,000 7,084,673
Non-Qualified Deferred Comp. Earni
All Other Compensation 234,688 321,153 254,436

23. Total Compensation 29,838,259 26,797,939 28,720,491
Christine A. Poon
Compensation History
Year Values in USD 2008 2007 2006
Salary 1,042,404 1,008,846 967,308
Bonus N/A N/A N/A
Other Annual Compensation/Fees N/A N/A N/A
Stock Awards 912,366 613,667 270,596
Option Awards 2,172,123 2,557,952 2,504,609
Restricted Stock Units N/A N/A N/A
Underlying Options/SARs (# of N/A N/A N/A
Securities)
Non-Equity Incentive Plan 3,721,500 3,718,000 2,389,600
Compensation
Change in Pension Value & 1,260,949 1,046,961 1,017,184
Non-Qualified Deferred Comp. Earni
All Other Compensation 1,293,151 1,198,421 1,021,083
Total Compensation 10,402,493 10,143,847 8,170,380
Robert J. Darretta
Compensation History
Year Values in USD 2006 2005 2004
Salary 1,023,846 983,846 950,000
Bonus N/A 891,000 874,500
Other Annual Compensation/Fees N/A 1,230,850 1,012,660
Stock Awards 626,226 N/A N/A
Johnson & Johnson

24. 09/23/2015 12 Mergent, Inc.
Year Values in USD 2006 2005 2004
Option Awards 3,229,546 N/A N/A
Restricted Stock Units N/A 674,994 N/A
Underlying Options/SARs (# of N/A 138,841 160,000
Securities)
Non-Equity Incentive Plan 2,574,880 N/A N/A
Compensation
Change in Pension Value & 2,231,163 N/A N/A
Non-Qualified Deferred Comp. Earni
All Other Compensation 1,577,864 44,273 42,750
Total Compensation 11,263,525 3,824,963 2,879,910
Russell C. Deyo
Compensation History
Year Values in USD 2011 2010 2009
Salary 895,269 867,377 831,838
Bonus N/A N/A N/A
Other Annual Compensation/Fees N/A N/A N/A
Stock Awards 783,714 622,707 611,372
Option Awards 1,258,614 1,058,060 1,159,245
Non-Equity Incentive Plan 3,967,694 3,831,820 3,608,760
Compensation
Change in Pension Value & 1,999,000 2,359,313 2,374,644
Non-Qualified Deferred Comp. Earni
Long-Term Compensation N/A N/A N/A
All Other Compensation 70,744 112,688 45,535
Total Compensation 8,975,035 8,851,965 8,631,394
Roger S. Fine
Nicholas J. Valeriani

25. Kaye I. Foster-Cheek
JoAnn Heffernan Heisen
Steven M. Rosenberg
Sherilyn S. McCoy
Compensation History
Johnson & Johnson
09/23/2015 13 Mergent, Inc.
Year Values in USD 2011 2010 2009
Salary 897,806 780,377 747,731
Stock Awards 705,437 679,311 407,599
Option Awards 1,132,912 1,154,247 772,833
Non-Equity Incentive Plan 3,924,807 3,221,760 2,626,630
Compensation
Change in Pension Value & 2,008,000 1,602,966 1,188,351
Non-Qualified Deferred Comp. Earni
All Other Compensation 64,716 78,443 36,890
Total Compensation 8,733,678 7,517,104 5,780,034
Colleen A. Goggins
Compensation History
Year Values in USD 2010 2009 2008
Salary 823,031 795,854 766,635
Stock Awards 634,107 634,037 630,240
Option Awards 1,077,431 1,202,179 1,022,731
Non-Equity Incentive Plan 3,404,650 3,784,070 3,687,885

26. Compensation
Change in Pension Value & 1,737,017 1,840,303 1,600,850
Non-Qualified Deferred Comp. Earni
All Other Compensation 62,378 60,453 69,844
Total Compensation 7,738,614 8,316,896 7,778,185
Donald M. Casey
Christian A. Koffmann
Joseph C. Scodari
Per A. Peterson
Compensation History
Year Values in USD 2006 2005 2004
Salary 830,692 801,077 761,808
Bonus N/A 750,268 798,750
Other Annual Compensation/Fees N/A 721,042 493,044
Stock Awards 579,841 N/A N/A
Option Awards 3,052,229 N/A N/A
Restricted Stock Units N/A 624,996 N/A
Underlying Options/SARs (# of N/A 128,557 150,000
Securities)
Non-Equity Incentive Plan 2,312,400 N/A N/A
Johnson & Johnson
09/23/2015 14 Mergent, Inc.
Year Values in USD 2006 2005 2004
Compensation
Change in Pension Value & 1,041,564 N/A N/A

27. Non-Qualified Deferred Comp. Earni
All Other Compensation 883,392 36,048 34,281
Total Compensation 8,700,118 2,933,431 2,087,883
Michael J. Dormer
Compensation History
Year Values in USD 2005 2004 2003
Salary 675,215 650,338 644,846
Bonus 940,500 553,875 515,000
Other Annual Compensation/Fees 605,790 449,006 384,024
Restricted Stock Units 624,996 N/A N/A
Underlying Options/SARs (# of 128,557 110,000 120,000
Securities)
All Other Compensation 30,385 29,265 29,018
Total Compensation 2,876,886 1,682,484 1,572,888
Directors
Alex Gorsky
Compensation History
Year Values in USD 2014 2013 2012
Salary 1,500,000 1,453,846 1,087,188
Stock Awards 9,467,380 5,988,975 2,790,229
Option Awards 41,168,139 2,669,999 1,482,631
Non-Equity Incentive Plan 5,018,779 4,867,361 3,407,287
Compensation
Change in Pension Value & 4,606,142 1,739,000 2,050,000
Non-Qualified Deferred Comp. Earni
All Other Compensation 228,866 191,779 159,774
Total Compensation 61,989,306 16,910,960 10,977,109
Mary Sue Coleman

28. Compensation History
Year Values in USD 2014 2013 2012
Other Annual Compensation/Fees 110,000 110,000 110,000
Stock Awards 154,924 144,989 144,913
All Other Compensation 20,000 20,710 20,000
Total Compensation 284,924 275,699 274,913
Johnson & Johnson
09/23/2015 15 Mergent, Inc.
D. Scott Davis
Compensation History
Year Values in USD 2014
Other Annual Compensation/Fees 110,000
Stock Awards 154,924
Total Compensation 264,924
Ian E. L. Davis
Compensation History
Year Values in USD 2014 2013 2012
Other Annual Compensation/Fees 58,366 110,000 110,000
Stock Awards N/A 144,989 144,913
Total Compensation 58,366 254,989 254,913
Susan L. Lindquist
Compensation History

29. Year Values in USD 2014 2013 2012
Salary N/A N/A N/A
Other Annual Compensation/Fees 130,000 130,000 110,000
Stock Awards 154,924 144,989 144,913
All Other Compensation 1,400 1,631 4,000
Total Compensation 286,324 276,620 258,913
Mark B. McClellan
Compensation History
Year Values in USD 2014 2013
Other Annual Compensation/Fees 110,000 27,500
Stock Awards 154,924 N/A
Total Compensation 264,924 27,500
Anne M. Mulcahy
Compensation History
Year Values in USD 2014 2013 2012
Other Annual Compensation/Fees 140,000 140,000 110,000
Stock Awards 164,924 144,989 144,913
All Other Compensation 20,000 N/A N/A
Total Compensation 324,924 284,989 254,913
Johnson & Johnson
09/23/2015 16 Mergent, Inc.
William D. Perez
Compensation History

30. Year Values in USD 2014 2013 2012
Other Annual Compensation/Fees 130,000 130,000 130,000
Stock Awards 154,924 144,989 144,913
All Other Compensation N/A 20,000 20,000
Total Compensation 284,924 294,989 294,913
Charles Prince
Compensation History
Year Values in USD 2014 2013 2012
Other Annual Compensation/Fees 130,000 130,000 130,000
Stock Awards 154,924 144,989 144,913
All Other Compensation N/A 20,524 10,000
Total Compensation 284,924 295,513 284,913
A. Eugene Washington
Compensation History
Year Values in USD 2014 2013 2012
Other Annual Compensation/Fees 110,000 110,000 9,167
Stock Awards 154,924 144,989 N/A
All Other Compensation 2,000 5,772 N/A
Total Compensation 266,924 260,761 9,167
Ronald A. Williams
Compensation History
Year Values in USD 2014 2013 2012
Other Annual Compensation/Fees 110,000 110,000 110,000
Stock Awards 154,924 144,989 144,913
All Other Compensation 20,000 N/A N/A
Total Compensation 284,924 254,989 254,913

31. Mary C. Beckerle
William C. Weldon
Compensation History
Johnson & Johnson
09/23/2015 17 Mergent, Inc.
Year Values in USD 2012 2011 2010
Salary 1,320,578 1,907,215 1,851,154
Bonus N/A N/A N/A
Other Annual Compensation/Fees N/A N/A N/A
Stock Awards 7,565,328 2,608,694 2,773,851
Option Awards 4,019,999 4,189,483 4,713,177
Restricted Stock Units N/A N/A N/A
Underlying Options/SARs (# of N/A N/A N/A
Securities)
Non-Equity Incentive Plan 13,447,666 14,336,394 12,043,200
Compensation
Change in Pension Value & 3,250,000 3,435,000 7,084,673
Non-Qualified Deferred Comp. Earni
All Other Compensation 234,688 321,153 254,436
Total Compensation 29,838,259 26,797,939 28,720,491
Christine A. Poon
Compensation History
Year Values in USD 2008 2007 2006
Salary 1,042,404 1,008,846 967,308
Bonus N/A N/A N/A
Other Annual Compensation/Fees N/A N/A N/A

32. Stock Awards 912,366 613,667 270,596
Option Awards 2,172,123 2,557,952 2,504,609
Restricted Stock Units N/A N/A N/A
Underlying Options/SARs (# of N/A N/A N/A
Securities)
Non-Equity Incentive Plan 3,721,500 3,718,000 2,389,600
Compensation
Change in Pension Value & 1,260,949 1,046,961 1,017,184
Non-Qualified Deferred Comp. Earni
All Other Compensation 1,293,151 1,198,421 1,021,083
Total Compensation 10,402,493 10,143,847 8,170,380
Robert J. Darretta
Compensation History
Year Values in USD 2006 2005 2004
Salary 1,023,846 983,846 950,000
Bonus N/A 891,000 874,500
Other Annual Compensation/Fees N/A 1,230,850 1,012,660
Stock Awards 626,226 N/A N/A
Option Awards 3,229,546 N/A N/A
Restricted Stock Units N/A 674,994 N/A
Underlying Options/SARs (# of N/A 138,841 160,000
Securities)
Johnson & Johnson
09/23/2015 18 Mergent, Inc.
Year Values in USD 2006 2005 2004
Non-Equity Incentive Plan 2,574,880 N/A N/A
Compensation
Change in Pension Value & 2,231,163 N/A N/A

33. Non-Qualified Deferred Comp. Earni
All Other Compensation 1,577,864 44,273 42,750
Total Compensation 11,263,525 3,824,963 2,879,910
James G. Cullen
Compensation History
Year Values in USD 2014 2013 2012
Other Annual Compensation/Fees 135,000 135,000 165,000
Stock Awards 154,924 144,989 144,913
All Other Compensation N/A 20,000 N/A
Total Compensation 289,924 299,989 309,913
David Satcher
Compensation History
Year Values in USD 2013 2012 2011
Other Annual Compensation/Fees 36,667 130,000 130,000
Stock Awards 144,989 144,913 99,974
All Other Compensation 22,247 10,000 20,000
Total Compensation 203,903 284,913 249,974
Leo F. Mullin
Compensation History
Year Values in USD 2014 2013 2012
Other Annual Compensation/Fees 130,000 130,000 130,000
Stock Awards 154,924 144,989 144,913
All Other Compensation N/A 21,884 16,666
Total Compensation 284,924 296,873 291,579
Michael M. E. Johns

34. Compensation History
Year Values in USD 2014 2013 2012
Other Annual Compensation/Fees 36,667 110,000 110,000
Stock Awards 154,924 144,989 144,913
All Other Compensation 20,000 10,000 20,000
Total Compensation 211,591 264,989 274,913
Johnson & Johnson
09/23/2015 19 Mergent, Inc.
Henry B. Schacht
Arnold G. Langbo
Compensation History
Year Values in USD 2010 2009 2008
Other Annual Compensation/Fees 30,000 120,000 120,000
Stock Awards 99,942 99,978 99,973
All Other Compensation 12,500 12,500 29,344
Total Compensation 142,442 232,478 249,317
Steven S. Reinemund
Compensation History
Year Values in USD 2008 2007 2006
Other Annual Compensation/Fees 38,000 103,167 95,000
Stock Awards 99,973 99,939 99,995
All Other Compensation 121,902 7,692 4,692
Total Compensation 259,875 210,798 199,687

35. Ann Dibble Jordan
Compensation History
Year Values in USD 2007 2006
Other Annual Compensation/Fees 36,500 105,000
Stock Awards 99,939 99,995
All Other Compensation 7,692 4,692
Total Compensation 144,131 209,687
M. Judah Folkman
Gerard N. Burrow
Insider Holdings
Holdings Summary
Total Insiders 41
Total Direct Shares 3,212,143
Total Indirect Shares 489,557
% Held By Insiders 0.12%
Johnson & Johnson
09/23/2015 20 Mergent, Inc.
Filer's Name Relation Direct Date
Prince Charles Director 08/06/2015
Stoffels Paulus Chief Scientific Officer 04/28/2015
Fasolo Peter VP, Global Human Resources 03/05/2015
Gorsky Alex Chairman, CEO 02/09/2015
Caruso Dominic J VP, Finance; CFO 02/09/2015
Cosgrove Stephen J Corporate Controller 01/16/2015
Ullmann Michael H VP, General Counsel 01/16/2015

36. Peterson Sandra E Group Worldwide Chairman 12/17/2014
Cullen James Director 09/10/2014
Coleman Mary Sue Director 05/08/2014
Perez William D Director 11/05/2013
Mullin Leo F Director 10/16/2013
Weldon William C Former Chairman of the Board 02/08/2013
Satcher David Director 02/05/2013
Lindquist Susan L Director 12/07/2012
Deyo Russell C VP, General Counsel 02/22/2012
Davis Ian Director 02/13/2012
Johns Michael M E Director 02/13/2012
Mulcahy Anne M Director 02/13/2012
Williams Ronald A Director 02/13/2012
Mccoy Sherilyn S Member, Executive Committee 02/09/2012
Goggins Colleen A Member, Executive Committee 01/10/2011
Langbo Arnold G Director 02/08/2010
Foster-Cheek Kaye I VP, Human Resources 12/31/2009
Valeriani Nicholas J VP, Strategy & Growth, Member,
Executive 08/25/2009
Committee, Director
Casey Donald M Jr. Member, Executive Committee 02/13/2009
Poon Christine A Vice Chairman, Director 02/13/2009
Scodari Joseph C Retired Exec Committee Member 05/28/2008
Reinemund Steven Director 02/11/2008
Peterson Per A Executive Committee Member 02/16/2007
Jordan Ann Dibble Director 02/12/2007
Johnson & Johnson
09/23/2015 21 Mergent, Inc.
Filer's Name Relation Direct Date
Darretta Robert J Vice Chairman, Director 12/15/2006

37. Dormer Michael J Member, Executive Committee 10/24/2006
Heisen Joann Heffernan VP, Chief Information Officer
12/30/2005
Schacht Henry B Director 04/28/2005
Burrow Gerard N Director 04/28/2005
Folkman M Judah Director 04/28/2005
Perkins Brian D Former Member Exec Committee 09/03/2004
Fine Roger S Retired Exec Committee Member 08/31/2004
Lenehan James T Former Vice Chairman/Director 05/31/2004
Wilson Robert N Retired Director/Vice Chairman 08/19/2003
Filer's Name Direct Shares Indirect Date Indirect Shares
Prince Charles 25,645 08/06/2015 800
Stoffels Paulus 94,473 0
Fasolo Peter 32,588 01/10/2011 0
Gorsky Alex 113,361 02/09/2015 1,417
Caruso Dominic J 88,734 02/09/2015 301
Cosgrove Stephen J 97,011 01/16/2015 2,133
Ullmann Michael H 72,251 01/16/2015 1,425
Peterson Sandra E 19,042 12/17/2013 0
Cullen James 1,489 10/21/2010 0
Coleman Mary Sue 12,601 0
Perez William D 8,122 11/05/2013 11,500
Mullin Leo F 26,195 10/16/2013 1,200
Weldon William C 307,273 02/08/2013 79,318
Satcher David 15,393 04/28/2005 0
Lindquist Susan L 14,605 02/02/2004 0
Deyo Russell C 141,443 02/22/2012 25,275
Davis Ian 4,193 07/19/2010 0
Johns Michael M E 14,356 0
Mulcahy Anne M 5,789 10/22/2009 0
Williams Ronald A 3,650 06/14/2011 0
Mccoy Sherilyn S 56,307 02/09/2012 18,608
Goggins Colleen A 107,832 01/10/2011 1,211
Langbo Arnold G 8,166 02/08/2010 1,600
Foster-Cheek Kaye I 4,583 12/31/2009 1,214

38. Valeriani Nicholas J 57,353 09/30/2009 10,076
Casey Donald M Jr. 22,536 02/13/2009 22,387
Poon Christine A 55,711 02/13/2009 178
Scodari Joseph C 18,646 04/30/2008 2,845
Reinemund Steven 7,567 0
Peterson Per A 16,043 02/16/2007 16,000
Jordan Ann Dibble 13,290 03/11/2003 0
Darretta Robert J 207,118 12/29/2006 1,938
Dormer Michael J 18,499 09/29/2006 878
Heisen Joann Heffernan 161,864 12/30/2005 8,176
Schacht Henry B 3,900 04/28/2005 0
Burrow Gerard N 10,267 04/28/2005 400
Folkman M Judah 3,811 11/05/2004 0
Johnson & Johnson
09/23/2015 22 Mergent, Inc.
Filer's Name Direct Shares Indirect Date Indirect Shares
Perkins Brian D 61,899 08/31/2004 1,734
Fine Roger S 191,226 08/31/2004 57,386
Lenehan James T 198,157 05/31/2004 10,525
Wilson Robert N 889,154 08/19/2003 211,032
Source: J3 Information Services Group
Insider Trades
3 Months
Summary (Direct Transactions Only) 3 Months 6 Months 12
Months 24 Months
Total Shares Bought 2,500 233,683 603,320 798,929

39. Total Buy Value 248,132 15,229,586 24,454,133 31,316,256
Total People Bought 1 2 8 9
Total Buy Transactions 1 3 21 41
Total Shares Sold 0 187,250 425,689 562,062
Total Sell Value 0 18,862,142 43,273,070 56,432,688
Total People Sold 0 1 7 9
Total Sell Transactions 0 1 16 32
End Date 06/23/2015 03/23/2015 09/23/2014 09/23/2013
Filer's Name Relation Title Off - Dir - 10% Trans. Date Form
Action Price Mkt Value
Prince Charles Director 1 - 1 - 0 08/06/2015 4 B 99.25
248,132
Filer's Name D/I Shares Holdings Rank 3m +/-
Prince Charles D 2,500 25,645 (4.27)
Transaction Ownership
Code Key : Code Key :
A - Acquired NO - UNKNOWN (added 06/04/2012) D
AB - Automatic Buy NP - Unknown (added 02/19/2013) I
Johnson & Johnson
09/23/2015 23 Mergent, Inc.
Transaction Ownership
Code Key : Code Key :
AS - Automatic Sell OE - Options Exercised
B - Buy PB - Private Buy
D - Disposed PS - Private Sell
IO - Initital Ownership S - Sell
- Direct

40. - Indirect
Source: J3 Information Services Group
09/23/2015 1 Mergent, Inc.
Johnson & Johnson
General Company Information
Principal Office
One Johnson & Johnson Plaza
New Brunswick, NJ 08933 USA
Phone 732 524-0400
Fax 732 214-0332
Auditor
PricewaterhouseCoopers LLP
Number of Employees
126,500 (Approximate Full-Time as of 12/31/2014)
Country of Incorporation
United States
Exchange And Ticker
NYS : JNJ
Primary SIC
2834 : Pharmaceutical preparations

41. Company Website
www.jnj.com
Primary NAICS
325412 : Pharmaceutical Preparation Manufacturing
Closing Stock Price 93.24 (as of 09/22/2015)
Incorporated
November 1887 , NJ, United States
Mergent Dividend Achiever Yes, # of Years: 46
Number of Shareholders
162,062 (record) (as of 02/17/2015)
Business Summary
Johnson & Johnson is a holding company. Through its
subsidiaries, Co. is organized into three segments.
The Consumer segment includes a range of products used in the
baby care, oral care, skin care,
over-the-counter pharmaceutical, women's health and wound
care markets. The Pharmaceutical segment
is focused on five therapeutic areas, including immunology,
infectious diseases, neuroscience, oncology,
and cardiovascular and metabolic diseases. The Medical
Devices segment includes a range of products
used in the orthopaedic, surgical care, specialty surgery,
cardiovascular care, diagnostics, diabetes care,
and vision care markets, which are distributed to wholesalers,
hospitals and retailers.

42. Johnson & Johnson
09/23/2015 2 Mergent, Inc.
Company Details
Pricing Summary
Time Period: 1 week
Yesterday 5 Days 30 Days
Close 93.24 93.39 92.82
Volume 10,618,620.00 14,211,147.00 25,633,357.00
52 Week High/Low : 109.07 - 90.73
% Price Change (100 Days) : -4.36
200-Day Moving Avg. : 98.98
Company News
12:02PM, 23 September 2015 - Report: J&J had plan to block
more FDA restrictions on Tylenol
- BioPharma Dive
11:11AM, 23 September 2015 - FDA Was Pressured By J&J Not
to Address Tylenol Liver Damage Risk:
Report
- AboutLawsuits.com
11:10AM, 23 September 2015 - U of Toronto to collaborate
with Johnson & Johnson on health start-ups
- Technology Transfer Tactics
9:52AM, 23 September 2015 - Nike, Johnson & Johnson,
Starbucks, And Others Join Pledge For 100%
Renewable Electricity
- CleanTechnica
9:00AM, 23 September 2015 - Dishman gets licence from JJ to
make TB drug raw material
- Money Control

43. 8:19AM, 23 September 2015 - Risperdal Litigation Pioneer
Stephen Sheller Featured in "DocuSerial"
about Johnson & Johnson, "America's Most Admired
Lawbreaker" by Steve Brill
- PR Newswire
3:21AM, 23 September 2015 - Dishman Pharma to make TB
drug exclusively for JJ
- Money Control
11:10PM, 22 September 2015 - Fortune 500 listed companies
pledge to use 100% renewable electricity
- Blue and Green Tomorrow
3:00PM, 22 September 2015 - Johnson & Johnson: A Gold
Standard Dividend Stock
- Seeking Alpha
11:03AM, 22 September 2015 - J&J faces Tylenol lobbying
allegations in first case to go to trial over med
Johnson & Johnson
09/23/2015 3 Mergent, Inc.
- FiercePharma
Corporate Events
Earnings Announcement Data - October 13 2015
: On Oct. 13, 2015, Co. announced its 3rd quarter earnings
before market (confirmed).
Conference Call Announcements - October 13 2015
: On Oct. 13, 2015, Co. scheduled a conference call at 12:30pm.
Conference Call Announcements - July 14 2015
: On July 14, 2015, Co. scheduled a conference call at 12:30pm.
Earnings Announcement Data - July 14 2015
: On July 14, 2015, Co. announced its 2nd quarter earnings
(confirmed).

44. Earnings Announcement Data - April 14 2015
: On Apr. 14, 2015, Co. announced its 1st quarter earnings
before market (confirmed).
Earnings Announcement Data - April 14 2015
: On Apr. 14, 2015, Co. announced its 1st quarter earnings
before market (confirmed).
Conference Call Announcements - April 14 2015
: On Apr. 14, 2015, Co. scheduled a conference call at 12:30pm.
Key Executives
Alex Gorsky Age Salary
Chairman,Chief Executive Officer 55 1,500,000
Dominic Caruso Age Salary
Vice President,Chief Financial Officer 57 878,115
Peter Fasolo Age Salary
Vice President 52 534,769
Michael Ullmann Age Salary
Vice President,General Counsel 57 591,346
Paulus Stoffels Age Salary
Chief Scientific Officer 53 1,075,423
Key Financials
(In USD as of 06/28/2015)
Income Statement
Revenue 71,882m
Net Income 16,106m
EPS from Continuing Operations 5.69
EPS - Net Income - Diluted 5.69
Revenue per Share 25.93
Balance Sheet
Total Assets 132,036m

45. Total Liabilities 60,905m
Shareholders' Equity 71,131m
Total Assets per Share 47.68
Net Assets per Share 25.69
Johnson & Johnson
09/23/2015 4 Mergent, Inc.
Cash Flows
Cash from Operations 17,091m
Cash from Investing -7,530m
Cash from Financing -12,065m
Capital Expenditures 3,555m
Cash Flow per Share 6.08
Financial Highlights
Financial Highlights as of 12/28/2014 in USD
Income Statement (In Thousands)
Total Revenue 74,331,000
EBITDA 24,927,000
Operating Income 20,959,000
Net Income 16,323,000
Revenue per Share 26.48
EPS from Continuing Operations 5.70
EPS - Net Income - Diluted 5.70
Share Outstanding 2,783,223
Weighted Average Shares Outstanding - Basic 2,815,200
Weighted Average Shares Outstanding - Diluted 2,863,900
Earnings per Share - Basic 5.80
Balance Sheet (In Thousands)
Total Assets 131,119,000
Current Assets 59,311,000

46. Total Liabilities 61,367,000
Long Term Debt 15,122,000
Stockholders' Equity 69,752,000
Total Assets per Share 47.11
Current Liabilities 25,085,000
Net Assets per Share 25.06
Cash Flow Statement (In Thousands)
Cash from Operations 18,471,000
Cash from Investing (12,305,000)
Cash from Financing (12,260,000)
Capital Expenditures 3,714,000
Cash Flow per Share 6.45
Cash & Cash Equivalents, Beginning of Year 20,927,000
Cash & Cash Equivalents, End of Year 14,523,000
Stock Price and Valuation (Data as of 09/22/2015)
Market Cap(mil) 258,191
Share Outstanding(000's) 2,769,106
PE Ratio 16.3866
Dividend Per Share(TTM) 2.9
Earning Per Share(TTM) 5.78
Last Closing Price 93.24
Previous Trading Day Range 91.88 - 93.44
52 Week Range 90.73 - 109.07
7 Day Average Closing Price 93.94
30 Day Average Closing Price 93.44
Johnson & Johnson
09/23/2015 5 Mergent, Inc.
200 Day Average Closing Price 98.98
Beta 0.55
High Price Last 3 Mos. 101.11
Low Price Last 3 Mos. 90.73

47. Avg Daily Volume Last 3 Mos. 8,391,457.25
Management Effectiveness
Revenue per Employee 589,211
Net Income per Employee 129,390
ROA % (Net) 12.41
ROE % (Net) 22.76
ROI % (Operating) 23.26
Profitability Ratios
Gross Margin 69.40
Operating Margin 28.20
EBITDA Margin % 33.54
Calculated Tax Rate % 20.62
Profit Margin (TTM) 21.96
Valuation Ratios
Price/Earnings (TTM) 18.06
Price/Book (TTM) 4.19
Price/Cash Flow(TTM) 15.97
Asset Management
Total Asset Turnover 0.57
Receivables Turnover 6.57
Inventory Turnover 2.83
Property Plant & Equip Turnover 4.54
Cash & Equivalents Turnover 4.21
Debt Management
Interest Coverage 44.98
Long Term Debt/Equity 0.22
Long Term Debt as % of Invested Capital 17.08
Total Debt/Equity 0.27
Accounts Payable Turnover 10.73
Accrued Expenses Turnover 5.25
Liquidity Indicators
Quick Ratio 1.76
Current Ratio 2.36
Net Current Assets as % of Total Assets 26.10
Free Cash Flow per Share 5.26

48. Revenue to Assets 0.57
Consensus Estimates 2015Ae 2015Q3e 2015Q4e
Earnings Per Share 6.16 1.46 1.44
Revenue 70,714.15 17,502.00 18,012.96
EBITDA 23,750.63 5,691.94 5,272.88
Property
Co. maintains its principal executive offices in New Brunswick,
NJ.
Co.'s subsidiaries operate 134 manufacturing facilities
occupying approx. 21,500,000 sq. ft. of floor space.
Johnson & Johnson
09/23/2015 6 Mergent, Inc.
The following table sets forth information regarding the
manufacturing facilities used by the industry
segments of Co.'s business as of Dec. 28, 2014:
Segment [1]Sq. Ft.
Consumer 7,213
Pharmaceutical 7,404
Medical Devices 6,850
Total 21,467
[1]In thousands
The following table sets forth information regarding the
locations of Co.'s manufacturing facilities by
geographic areas as of Dec. 28, 2014:

49. Geographic Area [1]Sq. Ft.
U.S. (42) 5,892
Europe (41) 7,673
Western Hemisphere, excluding U.S. (15) 3,005
Africa, Asia and Pacific (36) 4,897
Total 21,467
[1]In thousands
In addition, Co. and its subsidiaries maintain several office and
warehouse facilities throughout the world.
Principal Executive Offices
One Johnson & Johnson Plaza
New Brunswick, NJ 08933
United States
Subsidiaries
SUBSIDIARY NAME PERCENT OWNED COUNTRY
Subsidiaries
Subsidiaries
Acclarent, Inc. 100% United States
ALZA Corporation 100% United States
Animas Corporation 100% United States
Aragon Pharmaceuticals, Inc. 100% United States
Biosense Webster, Inc. 100% United States
CNA Development LLC 100% United States
Codman & Shurtleff, Inc. 100% United States
Cordis Corporation 100% United States
Cordis International Corporation 100% United States
Cordis LLC 100% United States
DePuy Mitek Holding Corporation 100% United States
DePuy Mitek, LLC 100% United States
DePuy Orthopaedics, Inc. 100% United States
DePuy Products, Inc. 100% United States

50. Johnson & Johnson
09/23/2015 7 Mergent, Inc.
SUBSIDIARY NAME PERCENT OWNED COUNTRY
DePuy Spine, LLC 100% United States
DePuy Synthes Sales, Inc. 100% United States
DePuy Synthes, Inc. 100% United States
Diabetes Diagnostics, Inc. 100% United States
Ethicon Endo-Surgery, Inc. 100% United States
Ethicon Endo-Surgery, LLC 100% United States
Ethicon LLC 100% United States
Ethicon US, LLC 100% United States
Ethicon, Inc. 100% United States
Flexible Stenting
Solution
s, Inc. 100% United States
J&J Holdings (Nevada), Inc. 100% United States
Janssen Alzheimer Immunotherapy 100% United States
Research & Development, LLC
Janssen Biotech, Inc. 100% United States
Janssen Global Services, LLC 100% United States
Janssen Oncology, Inc. 100% United States
Janssen Ortho LLC 100% United States
Janssen Pharmaceuticals, Inc. 100% United States

51. Janssen Products, LP 100% United States
Janssen Research & 100% United States
Development, LLC
Janssen Scientific Affairs, LLC 100% United States
Janssen Supply Group, LLC 100% United States
Janssen-Cilag Manufacturing, LLC 100% United States
JJHC, LLC 100% United States
JNJ International Investment LLC 100% United States
Johnson & Johnson (Middle 100% United States
East) Inc.
Johnson & Johnson Consumer 100% United States
Companies, Inc.
Johnson & Johnson Development 100% United States
Corporation
Johnson & Johnson Finance 100% United States
Corporation
Johnson & Johnson Health Care 100% United States
Systems Inc.
Johnson & Johnson International 100% United States
Johnson & Johnson Japan Inc. 100% United States
Johnson & Johnson Sales and 100% United States
Logistics Company, LLC
Johnson & Johnson Services, 100% United States
Inc.
Johnson & Johnson Urban 100% United States

52. Renewal Associates
Johnson & Johnson Vision Care, 100% United States
Inc.
JOM Pharmaceutical Services, Inc. 100% United States
LifeScan LLC 100% United States
LifeScan Products, LLC 100% United States
LifeScan, Inc. 100% United States
Johnson & Johnson
09/23/2015 8 Mergent, Inc.
SUBSIDIARY NAME PERCENT OWNED COUNTRY
McNeil Consumer Pharmaceuticals Co. 100% United States
McNeil Healthcare LLC 100% United States
McNeil LA LLC 100% United States
McNEIL MMP, LLC 100% United States
McNeil Nutritionals, LLC 100% United States
McNEIL-PPC, Inc. 100% United States
Mentor Texas L.P. 100% United States
Mentor Worldwide LLC 100% United States
Micro Typing Systems, Inc. 100% United States
Micrus Endovascular LLC 100% United States

53. Middlesex Assurance Company Limited 100% United States
Neutrogena Corporation 100% United States
Noramco, Inc. 100% United States
OMJ Pharmaceuticals, Inc. 100% United States
Omrix Biopharmaceuticals, Inc. 100% United States
Ortho Biologics LLC 100% United States
Ortho-Clinical Diagnostics, Inc. 100% United States
Rutan Realty LLC 100% United States
Scios LLC 100% United States
SterilMed, Inc. 100% United States
Synthes USA Products, LLC 100% United States
Synthes USA, LLC 100% United States
Synthes, Inc. 100% United States
The Anspach Effort, LLC 100% United States
Wellness & Prevention, Inc. 100% United States
Almaco Holding AG 100% Switzerland
Apsis 100% France
Apsis Germany GmbH 100% Germany
Beijing Dabao Cosmetics Co., Ltd. 100% China (Peoples
Rep. Of)
Berna Biotech Korea Corporation 100% Korea (South)
Berna Rhein B.V. 100% Netherlands
Biosense Webster (Israel) Ltd. 100% Israel
Cilag Advanced Technologies GmbH 100% Switzerland

54. Cilag AG 100% Switzerland
Cilag GmbH International 100% Switzerland
Cilag Holding AG 100% Switzerland
Cilag Pharmaceuticals GmbH 100% Switzerland
Cilag Products GmbH 100% Switzerland
Cordis de Mexico, S.A. de C.V. 100% Mexico
Cordis Europa NV 100% Netherlands
Corimmun GmbH 100% Germany
Crucell Holland B.V. 100% Netherlands
Crucell N.V. 100% Netherlands
Crucell Sweden AB 100% Sweden
Crucell Switzerland AG 100% Switzerland
DePuy (Ireland) 100% Ireland
DePuy France 100% France
DePuy International (Holdings) 100% United Kingdom
Limited
Johnson & Johnson
09/23/2015 9 Mergent, Inc.
SUBSIDIARY NAME PERCENT OWNED COUNTRY
DePuy International Limited 100% United Kingdom

55. DePuy Medical Private Limited 100% India
DePuy Mitek Sarl 100% Switzerland
DePuy Synthes Apollo Limited 100% Ireland
DePuy Synthes Eos Limited 100% Ireland
DePuy Synthes Gorgan Limited 100% Ireland
DePuy Synthes Jason Limited 100% Ireland
DePuy Synthes Leto S.A.R.L. 100% Ireland
DePuy UK Holdings Limited 100% United Kingdom
EES Holdings de Mexico, S. de R.L. 100% Mexico
de C.V.
Ethicon 100% France
Ethicon Ireland 100% Ireland
Ethicon PR Holdings 100% Ireland
Ethicon Women's Health & 100% Switzerland
Urology Sarl
Ethnor Farmaceutica, S.A. 100% Venezuela
FMS Future Medical System SA 100% Switzerland
GMED Healthcare BVBA 100% Belgium
J.C. General Services CVBA 100% Belgium
Janssen Alzheimer Immunotherapy 100% Ireland
Janssen Alzheimer Immunotherapy 100% Ireland
(Holding) Limited
Janssen Biologics (Ireland) 100% Ireland
Janssen Biologics B.V. 100% Netherlands
Janssen Cilag Farmaceutica S.A. 100% Argentina

56. Janssen de Mexico S. de R.L. de 100% Mexico
C.V.
Janssen Inc. 100% Canada
Janssen Infectious 100% Belgium
Diseases-Diagnostics BVBA
Janssen Korea Ltd. 100% Korea (South)
Janssen Pharmaceutica NV 100% Belgium
Janssen Pharmaceutical 100% Ireland
Janssen Pharmaceutical Holdings 100% Ireland
Janssen Pharmaceutical K.K. 100% Japan
Janssen R&D Ireland 100% Ireland
Janssen-Cilag 100% France
Janssen-Cilag AB 100% Sweden
Janssen-Cilag AG 100% Switzerland
Janssen-Cilag B.V. 100% Netherlands
Janssen-Cilag Farmaceutica Ltda. 100% Brazil
Janssen-Cilag Farmaceutica, Lda. 100% Portugal
Janssen-Cilag GmbH 100% Germany
Janssen Cilag Limited 100% Thailand
Janssen-Cilag Limited 100% United Kingdom
Janssen-Cilag NV 100% Belgium
Janssen-Cilag OY 100% Finland
Janssen-Cilag Pharma GmbH 100% Austria
Janssen-Cilag Pharmaceutical 100% Greece

57. Johnson & Johnson
09/23/2015 10 Mergent, Inc.
SUBSIDIARY NAME PERCENT OWNED COUNTRY
S.A.C.I.
Janssen-Cilag Pty Ltd 100% Australia
Janssen-Cilag S.p.A. 100% Italy
Janssen-Cilag, C.A. 100% Venezuela
Janssen-Cilag, S.A. 100% Spain
Janssen-Cilag, S.A. de C.V. 100% Mexico
J-C Health Care Ltd. 100% Israel
JJC Acquisition Company B.V. 100% Netherlands
Johnson & Johnson (China) 100% China (Peoples
Investment Ltd. Rep. Of)
Johnson & Johnson (China) Ltd. 100% China (Peoples
Rep. Of)
Johnson & Johnson (Hong Kong) 100% Hong Kong
Limited
Johnson & Johnson (Ireland) 100% Ireland
Limited
Johnson & Johnson (New 100% New Zealand

58. Zealand) Limited
Johnson & Johnson 100% Philippines
(Philippines), Inc.
Johnson & Johnson 100% South Africa
(Proprietary) Limited
Johnson & Johnson (Thailand) 100% Thailand
Ltd.
Johnson & Johnson AB 100% Sweden
Johnson & Johnson AG 100% Switzerland
Johnson & Johnson Consumer 100% Thailand
(Thailand) Limited
Johnson & Johnson Consumer B.V. 100% Netherlands
Johnson & Johnson Consumer 100% France
Holdings France
Johnson & Johnson Consumer 100% United Kingdom
Services EAME Ltd.
Johnson & Johnson de Argentina 100% Argentina
S.A.C. e. I.
Johnson & Johnson de Chile S.A. 100% Chile
Johnson & Johnson de Colombia 100% Colombia
S.A.
Johnson & Johnson de Mexico, 100% Mexico
S.A. de C.V.
Johnson & Johnson de 100% Venezuela
Venezuela, S.A.

59. Johnson & Johnson del Ecuador 100% Ecuador
S.A.
Johnson & Johnson del Peru S.A. 100% Peru
Johnson & Johnson do Brasil 100% Brazil
Industria E Comercio de Produtos
Para Saude Ltda.
Johnson & Johnson European 100% Ireland
Treasury Company
Johnson & Johnson
09/23/2015 11 Mergent, Inc.
SUBSIDIARY NAME PERCENT OWNED COUNTRY
Johnson & Johnson Finance 100% United Kingdom
Limited
Johnson & Johnson Financial 100% Germany
Services GmbH
Johnson & Johnson Gesellschaft 100% Austria
m.b.H.
Johnson & Johnson GmbH 100% Germany
Johnson & Johnson Group 100% Germany
Holdings GmbH

60. Johnson & Johnson Hellas 100% Greece
Commercial and Industrial S.A.
Johnson & Johnson Holding GmbH 100% Germany
Johnson & Johnson Inc. 100% Canada
Johnson & Johnson Industrial 100% Brazil
Ltda.
Johnson & Johnson 100% Ireland
International Financial Services
Company
Johnson & Johnson K.K. 100% Japan
Johnson & Johnson Kft. 100% Hungary
Johnson & Johnson Korea 100% Korea (South)
Selling & Distribution Limited
Liability Company
Johnson & Johnson Korea, Ltd. 100% Korea (South)
Johnson & Johnson Limitada 100% Portugal
Johnson & Johnson Limited 100% India
Johnson & Johnson Limited 100% United Kingdom
Johnson & Johnson LLC 100% Russia
Johnson & Johnson Luxembourg 100% Luxembourg
Finance Company Sarl
Johnson & Johnson Management 100% United Kingdom
Limited
Johnson & Johnson Medical 100% China (Peoples
(China) Ltd. Rep. Of)

61. Johnson & Johnson Medical 100% South Africa
(Pty) Limited
Johnson & Johnson Medical 100% China (Peoples
(Shanghai) Ltd. Rep. Of)
Johnson & Johnson Medical 100% China (Peoples
(Suzhou) Ltd. Rep. Of)
Johnson & Johnson Medical B.V. 100% Netherlands
Johnson & Johnson Medical GmbH 100% Germany
Johnson & Johnson Medical 100% Korea (South)
Korea Limited
Johnson & Johnson Medical 100% United Kingdom
Limited
Johnson & Johnson Medical 100% Mexico
Mexico, S.A. de C.V.
Johnson & Johnson Medical NV 100% Belgium
Johnson & Johnson Medical 100% Austria
Johnson & Johnson
09/23/2015 12 Mergent, Inc.
SUBSIDIARY NAME PERCENT OWNED COUNTRY
Products GmbH

62. Johnson & Johnson Medical Pty 100% Australia
Ltd
Johnson & Johnson Medical S.A. 100% Argentina
Johnson & Johnson Medical 100% Italy
S.p.A.
Johnson & Johnson Medical, 100% Venezuela
S.C.S.
Johnson & Johnson Middle East 100% United Arab
FZ-LLC Emirates
Johnson & Johnson Pacific Pty. 100% Australia
Limited
Johnson & Johnson Poland Sp. z 100% Poland
o.o.
Johnson & Johnson Pte. Ltd. 100% Singapore
Johnson & Johnson Pty. Limited 100% Australia
Johnson & Johnson S.p.A. 100% Italy
Johnson & Johnson SDN. BHD. 100% Malaysia
Johnson & Johnson Sihhi 100% Turkey
Malzeme Sanayi Ve Ticaret Limited
Sirketi
Johnson & Johnson Swiss 100% United Kingdom
Finance Company Limited
Johnson & Johnson Taiwan Ltd. 100% Taiwan
Johnson & Johnson Vision Care 100% Ireland
(Ireland)

63. Johnson & Johnson, prodaja 100% Slovenia
medicinskih in farmacevtskih
izdelkov, d.o.o.
Johnson & Johnson, S.A. 100% Spain
Johnson & Johnson, S.A. de C.V. 100% Mexico
Johnson & Johnson, s.r.o. 100% Czech Republic
Latam International Investment 100% Ireland
Company
Latam Properties Holdings 100% Ireland
LifeScan Scotland Limited 100% United Kingdom
McNeil AB 100% Sweden
McNeil GmbH & Co. oHG 100% Germany
McNeil Healthcare (UK) Limited 100% United Kingdom
McNeil Manufacturing Pty Ltd 100% Australia
McNeil Products Limited 100% United Kingdom
McNeil Sweden AB 100% Sweden
Medos International Sarl 100% Switzerland
Medos Sarl 100% Switzerland
Mentor Medical Systems B.V. 100% Netherlands
Mentor Medical Systems C.V. 100% Netherlands
OBTECH Medical Sarl 100% Switzerland
OMJ Ireland 100% Ireland
OMJ PR Holdings 100% Ireland
Omrix Biopharmaceuticals Ltd. 100% Israel

64. Johnson & Johnson
09/23/2015 13 Mergent, Inc.
SUBSIDIARY NAME PERCENT OWNED COUNTRY
Ortho-Clinical Diagnostics 100% France
Ortho-Clinical Diagnostics 100% United Kingdom
Ortho-Clinical Diagnostics GmbH 100% Germany
Ortho-Clinical Diagnostics K.K. 100% Japan
Ortho-Clinical Diagnostics NV 100% Belgium
P.T. Johnson & Johnson 100% Indonesia
Indonesia
Shanghai Elsker Mother & Baby 100% China (Peoples
Co., Ltd Rep. Of)
Shanghai Johnson & Johnson 100% China (Peoples
Pharmaceuticals, Ltd. Rep. Of)
Synthes (Canada) Ltd. 100% Canada
Synthes (Shanghai) Medical Trading 100% China (Peoples
Co., Ltd. Rep. Of)
Synthes (Suzhou) Medical Co., Ltd. 100% China (Peoples
Rep. Of)
Synthes Australia Pty Ltd 100% Australia

65. Synthes Colombia S.A.S. 100% Colombia
Synthes Finanz AG 100% Switzerland
SYNTHES GmbH 100% Germany
Synthes GmbH 100% Switzerland
Synthes Holding AG 100% Switzerland
Synthes Industria e Comercio Ltda. 100% Brazil
Synthes Limited 100% United Kingdom
Synthes Lux Finance S.ar.l. 100% Luxembourg
Synthes Lux Holding S.ar.l. 100% Luxembourg
Synthes Luxembourg, S.ar.l. 100% Luxembourg
Synthes Medical Private Limited 100% India
Synthes Produktions GmbH 100% Switzerland
Synthes Tuttlingen GmbH 100% Germany
Synthes-Stratec S.A. 100% Spain
Tasmanian Alkaloids Pty. Ltd. 100% Australia
Tibotec-Virco Comm. VA 100% Belgium
Turnbuckle Investment Company 100% Ireland
Vania Expansion 100% France
Xian-Janssen Pharmaceutical Ltd. 100% China (Peoples
Rep. Of)
Long Term Debt
Dec. 28, 2014, $15,129,000,000 (including current portion of
$7,000,000) comprised of:

66. -- 01 -- $898,000,000 2.15% notes, due 2016.
-- 02 -- $800,000,000 long-term debt, bearing interest at three
month London Interbank Offered Rate
(LIBOR) plus 0.07% FRN (effective interest rate was 0.31% at
Dec. 28, 2014), due 2016.
-- 03 -- $398,000,000 0.70% notes, due 2016.
-- 04 -- $1,000,000,000 5.55% debentures, due 2017.
Johnson & Johnson
09/23/2015 14 Mergent, Inc.
-- 05 -- $697,000,000 1.125% notes, due 2017.
-- 06 -- $898,000,000 5.15% debentures, due 2018.
-- 07 -- $597,000,000 1.65% notes, due 2018.
-- 08 -- $1,216,000,000 4.75% notes, due 2019.

67. -- 09 -- $497,000,000 1.875% notes, due 2019.
-- 10 -- $158,000,000 3% zero coupon convertible subordinated
debentures, due 2020.
-- 11 -- $543,000,000 2.95% debentures, due 2020.
-- 12 -- $446,000,000 3.55% notes, due 2021.
-- 13 -- $349,000,000 2.45% notes, due 2021.
-- 14 -- $250,000,000 6.73% debentures, due 2023.
-- 15 -- $812,000,000 3.375% notes, due 2023.
-- 16 -- $772,000,000 5.50% notes, due 2024.
-- 17 -- $297,000,000 6.95% notes, due 2029.
-- 18 -- $500,000,000 4.95% debentures, due 2033.
-- 19 -- $865,000,000 4.375% notes, due 2033.
-- 20 -- $995,000,000 5.95% notes, due 2037.

68. -- 21 -- $700,000,000 5.85% debentures, due 2038.
-- 22 -- $539,000,000 4.50% debentures, due 2040.
-- 23 -- $298,000,000 4.85% notes, due 2041.
-- 24 -- $499,000,000 4.50% notes, due 2043.
-- 25 -- $105,000,000 other long-term debt.
Line of Credit: Co. has access to substantial sources of funds at
several banks worldwide. In
Sept. 2014, Co. secured a 364-day Credit Facility. Total credit
available to Co. approximates
$10,000,000,000, which expires on Sept. 17, 2015. Interest
charged on borrowings under the credit line
agreements is based on either bids provided by banks, the prime
rate or LIBOR, plus applicable margins.
For details see below.
Expanded Long Term Debt
CUSIP Issuer Name Issue Description Ticker

69. Johnson & Johnson
09/23/2015 15 Mergent, Inc.
CUSIP Issuer Name Issue Description Ticker
478160AB0 JOHNSON & JOHNSON NT JNJ
478160AA2 JOHNSON & JOHNSON NT JNJ
478160AC8 JOHNSON & JOHNSON NT JNJ
478160AD6 JOHNSON & JOHNSON NT JNJ
218525AA1 CORDIS CORPORATION SUB DEB JNJ
152342AB7 CENTOCOR INCORPORATED SUB DEB CONV
JNJ
152342AA9 CENTOCOR INCORPORATED SUB NT CONV
JNJ
4781609A0 JOHNSON & JOHNSON NT REG S JNJ
478160AE4 JOHNSON & JOHNSON NT JNJ
421969AA4 HEARTPORT INCORPORATED SUB NT CONV
RULE 144A JNJ
421969AC0 HEARTPORT INCORPORATED SUB NT CONV
JNJ
152342AE1 CENTOCOR INCORPORATED SUB DEB CONV
JNJ
022615AD0 ALZA CORPORATION SUB DEB CONV JNJ

70. 808905AB9 SCIOS INCORPORATED SUB NT CONV JNJ
808905AA1 SCIOS INCORPORATED SUB NT CONV RULE
144A JNJ
478160AK0 JOHNSON & JOHNSON DEB JNJ
022615AB4 ALZA CORPORATION LIQUID YIELD OPT NT
JNJ
(LYONS)
478160AP9 JOHNSON & JOHNSON GLOBAL NT JNJ
478160AM6 JOHNSON & JOHNSON GLOBAL DEB JNJ
022615AC2 ALZA CORPORATION SUB NT ZERO CPN
CONV JNJ
(LYON)
478160AQ7 JOHNSON & JOHNSON GLOBAL NT JNJ
478160AS3 JOHNSON & JOHNSON EUR$ GLOBAL NT JNJ
02261WAB5 ALZA CORPORATION SUB DEB ZERO CPN
CONV JNJ
02261WAA7 ALZA CORPORATION SUB DEB ZERO CPN
CONV JNJ
RULE 144A
478160AF1 JOHNSON & JOHNSON DEB JNJ
478160AG9 JOHNSON & JOHNSON DEB JNJ
478160AR5 JOHNSON & JOHNSON GBP$ GLOBAL NT JNJ

71. 478160AJ3 JOHNSON & JOHNSON DEB JNJ
478160AL8 JOHNSON & JOHNSON GLOBAL DEB JNJ
478160AN4 JOHNSON & JOHNSON GLOBAL NT JNJ
CUSIP Coupon Maturity Active
478160AB0 8.87510/15/1990 No
478160AA2 9.12509/15/1992 No
478160AC8 8.508/15/1995 No
478160AD6 809/01/1998 No
218525AA1 12.2506/15/1999 No
152342AB7 6.7502/01/2001 No
152342AA9 7.2502/01/2001 No
4781609A0 607/19/2001 No
478160AE4 7.37506/29/2002 No
421969AA4 7.2505/01/2004 No
421969AC0 7.2505/01/2004 No
152342AE1 4.7502/15/2005 No
022615AD0 505/01/2006 No
808905AB9 5.508/15/2009 No
808905AA1 5.508/15/2009 No
Johnson & Johnson

72. 09/23/2015 16 Mergent, Inc.
CUSIP Coupon Maturity Active
478160AK0 6.62509/01/2009 No
022615AB4 012/21/2010 No
478160AP9 5.1508/15/2012 No
478160AM6 3.805/15/2013 No
022615AC2 007/14/2014 No
478160AQ7 5.5508/15/2017 Yes
478160AS3 -11/06/2019 Yes
02261WAB5 007/28/2020 Yes
02261WAA7 007/28/2020 No
478160AF1 6.7311/15/2023 Yes
478160AG9 8.7211/01/2024 No
478160AR5 -11/06/2024 Yes
478160AJ3 6.9509/01/2029 Yes
478160AL8 4.9505/15/2033 Yes
478160AN4 5.9508/15/2037 Yes
Capital Structure
Abbreviation Description Structure Type Exchange Ticker
Market Cap

73. Com Com Common NYS JNJ 258,191,443,440
Business Segments
Business Analysis
Revenues
Report Date 12/28/2014 12/29/2013 12/30/2012 01/01/2012
Currency USD USD USD USD
Scale Millions Millions Millions Millions
Consumer 14,496 14,697 14,447 14,883
Pharmaceutical 32,313 28,125 25,351 24,368
Medical Devices & Diagnostics 27,522 28,490 27,426 25,779
Total 74,331 71,312 67,224 65,030
Operating Income
Report Date 01/02/2011 12/28/2014 12/29/2013 12/30/2012
Currency USD USD USD USD
Scale Millions Millions Millions Millions
Consumer 14,590 1,941 1,973 1,693
Pharmaceutical 22,396 11,696 9,178 6,075
Medical Devices & Diagnostics 24,601 7,953 5,261 7,187
Total 61,587 21,590 16,412 14,955
Report Date 01/01/2012 01/02/2011

74. Currency USD USD
Johnson & Johnson
09/23/2015 17 Mergent, Inc.
Report Date 01/01/2012 01/02/2011
Currency USD USD
Scale Millions Millions
Consumer 2,096 2,342
Pharmaceutical 6,406 7,086
Medical Devices & Diagnostics 5,263 8,272
Total 13,765 17,700
Geographic Analysis
Revenues
Report Date 12/28/2014
Currency USD
Scale Millions
United States 34,782
Europe 18,947
Western Hemisphere excluding U.S. 7,160

75. Asia-Pacific, Africa 13,442
Total 74,331
Report Date 12/29/2013
Currency USD
Scale Millions
United States 31,910
Europe 18,599
Western Hemisphere excluding U.S. 7,421
Asia-Pacific, Africa 13,382
Total 71,312
Johnson & Johnson
09/23/2015 18 Mergent, Inc.
Report Date 12/30/2012
Currency USD
Scale Millions
United States 29,830
Europe 16,945
Western Hemisphere excluding U.S. 7,207
Asia-Pacific, Africa 13,242

76. Total 67,224
Report Date 01/01/2012
Currency USD
Scale Millions
United States 28,908
Europe 17,129
Western Hemisphere excluding U.S. 6,418
Asia-Pacific, Africa 12,575
Total 65,030
Johnson & Johnson
09/23/2015 19 Mergent, Inc.
Report Date 01/02/2011
Currency USD
Scale Millions
United States 29,450
Europe 15,510
Western Hemisphere excluding U.S. 5,550
Asia-Pacific, Africa 11,077
Total 61,587

77. Johnson & Johnson (NYS: JNJ)
Report: J&J had plan to block more FDA restrictions on Tylenol
BioPharma Dive - 12:02PM, 23 September 2015
FDA Was Pressured By J&J Not to Address Tylenol Liver
Damage Risk:
Report
AboutLawsuits.com - 11:11AM, 23 September 2015
U of Toronto to collaborate with Johnson & Johnson on health
start-ups
Technology Transfer Tactics - 11:10AM, 23 September 2015
Nike, Johnson & Johnson, Starbucks, And Others Join Pledge
For 100%
Renewable Electricity
CleanTechnica - 9:52AM, 23 September 2015
Dishman gets licence from JJ to make TB drug raw material
Money Control - 9:00AM, 23 September 2015
Risperdal Litigation Pioneer Stephen Sheller Featured in
"DocuSerial"
about Johnson & Johnson, "America's Most Admired
Lawbreaker" by
Steve Brill

78. PR Newswire - 8:19AM, 23 September 2015
Dishman Pharma to make TB drug exclusively for JJ
Money Control - 3:21AM, 23 September 2015
Fortune 500 listed companies pledge to use 100% renewable
electricity
Blue and Green Tomorrow - 11:10PM, 22 September 2015
Johnson & Johnson: A Gold Standard Dividend Stock
Seeking Alpha - 3:00PM, 22 September 2015
J&J faces Tylenol lobbying allegations in first case to go to
trial over med
FiercePharma - 11:03AM, 22 September 2015
Alex Gorsky
Title : Chairman
Tenure : 27 Age : 55
Total Compensation : $61,989,306 %Change : 2.67
Education : -
Dominic J. Caruso
Title : Vice President
Johnson & Johnson (NYS: JNJ)

79. Key Officers
Tenure : 16 Age : 57
Total Compensation : $10,349,033 %Change : 0.26
Education : -
Peter M. Fasolo
Title : Vice President
Tenure : 5 Age : 52
Total Compensation : $3,621,281 %Change : -
Education : -
Michael H. Ullmann
Title : Vice President
Tenure : 26 Age : 57
Total Compensation : $5,960,691 %Change : 0.37
Education : -
Paulus Stoffels
Title : Chief Scientific Officer
Tenure : 13 Age : 53
Total Compensation : $18,339,317 %Change : 1.34

80. Education : -
Stephen J. Cosgrove
Title : Chief Accounting Officer
Tenure : - Age : -
Total Compensation : $- %Change : -
Education : -
Sandra E. Peterson
Title : Group Worldwide Chair
Tenure : 3 Age : 56
Total Compensation : $7,086,606 %Change : 0.26
Education : -
Douglas K. Chia
Title : Secretary
Tenure : 9 Age : -
Total Compensation : $- %Change : -
Education : -
Ronald A. Kapusta
Title : Division Officer

81. Tenure : 23 Age : 56
Total Compensation : $- %Change : -
Education : -
Lacey P. Elberg
Title : Assistant Secretary
Tenure : - Age : -
Total Compensation : $- %Change : -
Education : -
Total Institutions: 2,777 2,062
Total Shares Held: 2,117,236,303
% of Shares Held: 64.40%
Changes In:
New/Increased vs
Old/Decreased Positions: -259
Amount of Shares Held: -167,217,071
% of shares held change: -77.03%
64.40% Held By Institutions -77.03% Shares Held Change

82. New Positions Increased Positions Closed Positions Decreased
Positions Unchanged Positions
Institutions: 0 Institutions: 1,103 Institutions: 60
Institutions: 1,302 Institutions: 372
Shares: 0 Shares: 911,498,337 Shares: 9,450,411
Shares: 1,069,264,997 Shares: 136,472,969
% Change: 0.00% % Change: 88.02% % Change: 30.16%
% Change: 86.82% % Change: 51.89%
Top 25 Institution Holders
Johnson & Johnson (NYS: JNJ)
Institution Name New/Closed
Position
Filing
Date
Total
Shares
Total

83. Values
Change in
Shares
VANGUARD GROUP INC - 6/30/2015 169,928,015 16,561,185
1,032,227
STATE STREET CORP - 6/30/2015 150,057,349 14,624,585
(5,247,524)
BLACKROCK
INSTITUTIONAL TRUST
COMPANY
- 6/30/2015 74,883,668 7,298,162 (1,705,895)
FMR LLC - 6/30/2015 52,334,199 5,100,491 (9,100,250)
BANK OF NEW YORK
MELLON CORP
- 6/30/2015 43,498,631 4,239,377 (54,688)
WELLINGTON
MANAGEMENT CO LLP
- 6/30/2015 38,634,914 3,765,359 (239,427)

84. NORTHERN TRUST
CORP
- 6/30/2015 38,281,191 3,730,884 339,369
STATE FARM MUTUAL
AUTOMOBILE
INSURANCE CO
- 6/30/2015 37,878,592 3,691,648 0
BLACKROCK FUND
ADVISORS
- 6/30/2015 37,510,345 3,655,758 2,427,084
J P MORGAN CHASE &
CO
- 6/30/2015 34,415,048 3,354,091 (10,609,645)
MASSACHUSETTS
FINANCIAL SERVICES
CO /MA/

85. - 6/30/2015 30,006,715 2,924,454 (828,631)
BLACKROCK GROUP
LTD
- 6/30/2015 25,020,880 2,438,535 1,099,430
BANK OF AMERICA
CORP /DE/
- 6/30/2015 24,256,214 2,364,010 (611,519)
GEODE CAPITAL
MANAGEMENT LLC
- 6/30/2015 22,679,702 2,206,159 14,733
CAPITAL WORLD
INVESTORS
- 6/30/2015 21,950,000 2,139,247 (1,895,000)
AMERIPRISE FINANCIAL
INC

86. - 6/30/2015 19,881,466 1,937,322 1,488,439
PRICE T ROWE
ASSOCIATES INC /MD/
- 6/30/2015 18,936,971 1,845,597 (20,412)
WELLS FARGO &
CO/MN
- 6/30/2015 17,922,831 1,746,760 250,177
MORGAN STANLEY - 6/30/2015 17,264,545 1,682,603
760,241
BARROW HANLEY
MEWHINNEY &
STRAUSS INC
- 6/30/2015 15,632,757 1,523,568 (43,605)
FRANKLIN RESOURCES
INC
- 6/30/2015 15,181,005 1,479,540 361,602

87. GOLDMAN SACHS
GROUP INC/
- 6/30/2015 13,239,653 1,290,337 1,700,452
JOHNSON ROBERT
WOOD FOUNDATION
- 6/30/2015 13,000,000 1,266,980 0
- 6/30/2015 12,932,504 1,260,402 (1,267,994)
Institution Name New/Closed
Position
Filing
Date
Total
Shares
Total

88. Values
Change in
Shares
TIAA CREF
INVESTMENT
MANAGEMENT LLC
DEUTSCHE BANK AG - 6/30/2015 12,931,691 1,260,315
(2,373,836)
Johnson & Johnson (NYS: JNJ)
Results are the first 25 filings from the last 90 days.
For additional filings, please use Edgar Search
Click here for Edgar Search
JOHNSON & JOHNSON
Results - select format to view filing. Select to add the filing
to the Batch Printing list to download/print multiple filings at
once
Filing Type Filing Date Filing Size Accession Number View

89. Documents Select Section (View In Text Only)
4 09/10/2015 4kb 0001225208-15-
4 09/10/2015 4kb 0001225208-15-
4 09/10/2015 4kb 0001225208-15-
4 09/10/2015 4kb 0001225208-15-
SC 13G 08/28/2015 69kb 0000904454-15-000543 Entire Filing
4 08/12/2015 9kb 0000904454-15-
4 08/10/2015 4kb 0001225208-15-
10-Q 07/31/2015 4962kb 0000200406-15-000044 10-Q 2Q
8-K 07/14/2015 2058kb 0000200406-15-000042 8-
SC 13G 07/07/2015 72kb 0000904454-15-000449 Entire Filing
3 07/06/2015 5kb 0000904454-15-
11-K 06/25/2015 385kb 0000200406-15-000039 11-
11-K 06/25/2015 374kb 0000200406-15-000038 11-
11-K 06/25/2015 400kb 0000200406-15-000037 11-
Business Summary
Johnson & Johnson is a holding company. Through
its subsidiaries, Co. is organized into three

90. segments. The Consumer segment includes a
range of products used in the baby care, oral care,
skin care, over-the-counter pharmaceutical,
women's health and wound care markets. The
Pharmaceutical segment is focused on five
therapeutic areas, including immunology, infectious
diseases, neuroscience, oncology, and
cardiovascular and metabolic diseases. The
Medical Devices segment includes a range of
products used in the orthopaedic, surgical care,
specialty surgery, cardiovascular care, diagnostics,
diabetes care, and vision care markets, which are
distributed to wholesalers, hospitals and retailers.
Pricing Summary
Time Period: 1 week
Yesterday 5 Days 30 Days
Close 93.24 93.39 92.82
Volume 10,618,620.00 14,211,147.00 25,633,357.00
Key Executives
Alex Gorsky Age Salary
Chairman,Chief
Executive Officer

91. 55 1,500,000
Dominic Caruso Age Salary
Vice
President,Chief
Financial Officer
57 878,115
Peter Fasolo Age Salary
Vice President 52 534,769
Michael Ullmann Age Salary
Vice
President,General
Counsel
57 591,346
Paulus Stoffels Age Salary
Chief Scientific
Officer
53 1,075,423

92. Key Financials
(In USD as of 06/28/2015)
Income Statement
Revenue 71,882m
Net Income 16,106m
EPS from Continuing Operations 5.69
EPS - Net Income - Diluted 5.69
Revenue per Share 25.93
Balance Sheet
Total Assets 132,036m
Total Liabilities 60,905m
Shareholders' Equity 71,131m
Total Assets per Share 47.68
Net Assets per Share 25.69
Cash Flows
Cash from Operations 17,091m
Cash from Investing -7,530m
Cash from Financing -12,065m
Capital Expenditures 3,555m
Cash Flow per Share 6.08
Johnson & Johnson (NYS: JNJ)

93. Yesterday 5 Days 30 Days
52 Week
High/Low :
109.07 -
90.73
% Price
Change
(100 Days)
: -4.36
200-Day
Moving
Avg. : 98.98
Company News
12:02PM, 23 September 2015 - Report: J&J had
plan to block more FDA restrictions on Tylenol -
BioPharma Dive
11:11AM, 23 September 2015 - FDA Was
Pressured By J&J Not to Address Tylenol Liver
Damage Risk: Report - AboutLawsuits.com
11:10AM, 23 September 2015 - U of Toronto to

94. collaborate with Johnson & Johnson on health start-
ups - Technology Transfer Tactics
9:52AM, 23 September 2015 - Nike, Johnson &
Johnson, Starbucks, And Others Join Pledge For
100% Renewable Electricity - CleanTechnica
9:00AM, 23 September 2015 - Dishman gets
licence from JJ to make TB drug raw material -
Money Control
8:19AM, 23 September 2015 - Risperdal Litigation
Pioneer Stephen Sheller Featured in "DocuSerial"
about Johnson & Johnson, "America's Most
Admired Lawbreaker" by Steve Brill - PR Newswire
3:21AM, 23 September 2015 - Dishman Pharma to
make TB drug exclusively for JJ - Money Control
11:10PM, 22 September 2015 - Fortune 500 listed
companies pledge to use 100% renewable
electricity - Blue and Green Tomorrow
3:00PM, 22 September 2015 - Johnson & Johnson:
A Gold Standard Dividend Stock - Seeking Alpha
11:03AM, 22 September 2015 - J&J faces Tylenol
lobbying allegations in first case to go to trial over
med - FiercePharma
Corporate Events

95. Earnings Announcement Data - October 13 2015
Conference Call Announcements - October 13 2015
Conference Call Announcements - July 14 2015
Earnings Announcement Data - July 14 2015
Earnings Announcement Data - April 14 2015
Earnings Announcement Data - April 14 2015
Conference Call Announcements - April 14 2015
Johnson & Johnson (NYS: JNJ)
Exchange rate used is that of the Year End reported date
As Reported Annual Balance Sheet
Report Date 12/28/2014 12/29/2013 1 12/30/2012 01/01/2012
01/02/2011
Currency USD USD USD USD USD
Audit Status Not
Qualified
Not

96. Qualified
Not
Qualified
Not
Qualified
Not
Qualified
Consolidated Yes Yes Yes Yes Yes
Scale Millions Millions Millions Millions Millions
Cash & cash equivalents 14,523 20,927 14,911 24,542 19,355
Marketable securities 18,566 8,279 6,178 7,719 8,303
Accounts receivable, trade,
gross
11,260 12,046 11,775 10,942 10,114
Less: allowance for doubtful
accounts
275 333 466 361 340
Accounts receivable, trade,

97. net
10,985 11,713 11,309 10,581 9,774
Raw materials & supplies 1,214 1,224 1,416 1,206 1,073
Goods in process 2,461 2,612 2,262 1,637 1,460
Finished goods 4,509 4,042 3,817 3,442 2,845
Inventories 8,184 7,878 7,495 6,285 5,378
Deferred taxes on income 3,567 3,607 3,139 2,556 2,224
Prepaid expenses & other
receivables
3,486 4,003 3,084 2,633 2,273
Total current assets 59,311 56,407 46,116 54,316 47,307
Land & land improvements 833 885 793 754 738
Buildings & building
equipment
10,046 10,423 10,046 9,389 9,079
Machinery & equipment 22,206 22,527 21,075 19,182 18,032
Construction in progress 3,600 3,298 2,740 2,504 2,577
Property, plant & equipment,
cost

98. 36,685 37,133 34,654 31,829 30,426
Less: accumulated
depreciation
20,559 20,423 18,557 17,090 15,873
Property, plant & equipment,
net
16,126 16,710 16,097 14,739 14,553
Report Date 12/28/2014 12/29/2013 1 12/30/2012 01/01/2012
01/02/2011
Currency USD USD USD USD USD
Audit Status Not
Qualified
Not
Qualified
Not

99. Qualified
Not
Qualified
Not
Qualified
Consolidated Yes Yes Yes Yes Yes
Scale Millions Millions Millions Millions Millions
Intangible assets, net 27,222 27,947 28,752 18,138 16,716
Goodwill, net 21,832 22,798 22,424 16,138 15,294
Deferred taxes on income 3,396 3,872 4,541 6,540 5,096
Other assets 3,232 4,949 3,417 3,773 3,942
Total assets 131,119 132,683 121,347 113,644 102,908
Loans & notes payable 3,638 4,852 4,676 6,658 7,617
Accounts payable 7,633 6,266 5,831 5,725 5,623
Accrued liabilities 6,553 7,685 7,299 4,608 4,100
Accrued rebates, returns &
promotions
4,010 3,308 2,969 2,637 2,512
Accrued compensation &
employee related obligations

100. 2,751 2,794 2,423 2,329 2,642
Accrued taxes on income 500 770 1,064 854 578
Total current liabilities 25,085 25,675 24,262 22,811 23,072
Zero coupon convertible
subordinated debentures
158 179 205 199 194
Debentures 4,430 8,792 4,929 5,527 5,027
Notes 9,636 4,429 6,556 6,477 3,872
FRN 800 1,550 1,250 1,250 -
Other long-term debt 105 147 61 132 76
Total long-term debt 15,129 15,097 13,001 13,585 9,169
Less: current portion 7 1,769 1,512 616 13
Long-term debt 15,122 13,328 11,489 12,969 9,156
Deferred taxes on income 3,154 3,989 3,136 1,800 1,447
Pension benefits 4,547 2,950 4,488 3,937 2,175
Postretirement benefits 3,161 2,655 2,789 2,843 2,359
Postemployment benefits 2,062 1,872 1,452 1,129 1,379
Deferred compensation 599 693 747 863 820
Total employee related
obligations before current
benefits payable

101. 10,369 8,170 9,476 8,772 6,733
Less: current benefits
payable
(397) (386) (394) (419) (646)
Employee related obligations 9,972 7,784 9,082 8,353 6,087
Other liabilities 8,034 7,854 8,552 10,631 6,567
Total liabilities 61,367 58,630 56,521 56,564 46,329
Common stock 3,120 3,120 3,120 3,120 3,120
Report Date 12/28/2014 12/29/2013 1 12/30/2012 01/01/2012
01/02/2011
Currency USD USD USD USD USD
Audit Status Not
Qualified
Not
Qualified
Not

102. Qualified
Not
Qualified
Not
Qualified
Consolidated Yes Yes Yes Yes Yes
Scale Millions Millions Millions Millions Millions
Foreign currency translations (4,803) (202) (296) (1,526) (969)
Gains (losses) on securities 257 106 195 448 24
Employee benefit plans (6,317) (3,009) (5,717) (4,386) (2,686)
Gains (losses) on derivatives
& hedges
141 245 8 (168) 100
Accumulated other
comprehensive income (loss)
(10,722) (2,860) (5,810) (5,632) (3,531)
Retained earnings
(accumulated deficit)

103. 97,245 89,493 85,992 81,251 77,773
Total equity before treasury
stock
89,643 89,753 83,302 78,739 77,362
Less: common stock held in
treasury, at cost
19,891 15,700 18,476 21,659 20,783
Total shareholders' equity
(deficit)
69,752 74,053 64,826 57,080 56,579
1 Reclassified to conform with 2014 presentation
Johnson & Johnson (NYS: JNJ)
Annual Reports

104. Note: Company Reports selections are in PDF format. In order
to view PDF selections, you must have Adobe
Acrobat Reader
Year File Size Language
2014-12-28 10K or Int'l Equivalent 334K English
2013-12-31 Annual Report 3233K English
2013-12-29 10K or Int'l Equivalent 332K English
2012-12-30 10K or Int'l Equivalent 1196K English
2012-01-01 Annual Report 4770K English
2011-01-02 Annual Report 3161K English
2011-01-02 10K or Int'l Equivalent 50K English
2010-01-03 Annual Report 2465K English
2010-01-03 10K or Int'l Equivalent 66K English
2009-01-03 Annual Report 2465K English
2008-12-28 Annual Report 4226K English
2007-12-31 Annual Report 3531K English
2007-12-30 10K or Int'l Equivalent 479K English
2006-12-31 Annual Report 3647K English
2006-01-01 Annual Report 2193K English
2005-01-02 Annual Report 1828K English
2003-12-28 Annual Report 3381K English
2002-12-29 Annual Report 2301K English
2001-12-30 Annual Report 2089K English
2000-12-31 Annual Report 5491K English

105. 2000-01-02 Annual Report 2973K English
1999-01-03 Annual Report 2803K English
1997-12-28 Annual Report 3059K English